01—Abstract
Summary
Summary of the 10-K filed February 27, 2018. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. is one of the world's leading clinical contract research organizations, by revenue, solely focused on outsourced clinical development services for biotechnology, pharmaceutical and medical device companies.
For the year ended December 31, 2017, net service revenue was $386.5 milliona, up from $370.6 million in 2016, and net income was $39.1 million, compared with $13.4 million in 2016. Income from operations rose to $64.9 million from $52.5 million. Backlog grew by $40.5 million, or 8.4%, to $524.4 million at year-end, and net new business awards were $426.1 million for 2017.
The company generated 64%b of net service revenue from small biopharmaceutical companies, 25% from mid-sized companies and 11% from large pharmaceutical companies. Its top 10 customers accounted for 32.2% of net service revenue, and its largest customer for 5.3%. The balance sheet and capital structure are shaped by Cinven, a private equity owner, and founder Dr. August J.
Troendle, who together control a substantial majority of common stock. Cinven owned approximately 46.2% and Dr. Troendle about 29.2% at December 31, 2017. Total indebtedness was $222.6 millionc, comprising $152.6 million of term loan and $70.0 million of revolver borrowings, and the company was in compliance with its financial covenants.
During 2017 the company repurchased shares from Cinven in two transactions of 2,000,000 shares each, at $30.27d and $30.16 per share, and repurchased $155.6 million of common stock in total for the year. The filing also notes that Cinven-affiliated entities pledged their shares as collateral for a separate credit agreement, which could eventually affect controlled-company status.
The filing highlights risks including customer concentration, the potential for cancellations and backlog not converting at historical rates, fixed-fee contract overruns, foreign currency exposure (7.6% of revenue in non-U.S. dollar currencies), and the effects of the Tax Cuts and Jobs Act. The 2017 effective tax rate was 31.3%, reduced by tax reform, which the company estimates would otherwise have been 36.2%.
02—Key points
Key Highlights
- Net service revenue rose to $386.5 million in 2017 from $370.6 million in 2016, and total revenue reached $436.2 million including reimbursed out-of-pocket revenue.
- Net income increased to $39.1 million in 2017 from $13.4 million in 2016, with diluted EPS of $0.98 versus $0.37.
- Backlog increased $40.5 million, or 8.4%, to $524.4 million at December 31, 2017; approximately $285 million to $295 million is expected to convert to net service revenue in 2018.
- Net new business awards were $426.1 million in 2017, compared with $427.0 million in 2016 and $359.5 million in 2015.
- Revenue is concentrated in small and mid-sized biopharmaceutical customers (64% and 25% of net service revenue), with the top 10 customers representing 32.2% of net service revenue.
- Cinven owned approximately 46.2% and founder Dr. Troendle about 29.2% of common stock at year-end, giving them control over shareholder votes; the company is a 'controlled company' under NASDAQ rules.
- Total indebtedness was $222.6 million, and the company repurchased $155.6 million of common stock during 2017, including two 2,000,000-share purchases from Cinven.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2017filed February 27, 2018Financial Statements
FY2017 against FY2016
| Line item | FY2017FY2016 | Change |
|---|---|---|
| Revenue | $436.15M$421.58M | +3.5% |
| SG&A Expenses | $63.36M$61.51M | +3.0% |
| Operating Expenses | $371.29M$369.09M | +0.6% |
| Operating Income | $64.86M$52.49M | +23.6% |
| Net Income | $39.12M$13.43M | +191.4% |
| EPS (Basic) | $1.00$0.38 | +163.2% |
| EPS (Diluted) | $0.98$0.37 | +164.9% |
| Shares Outstanding (Basic) | 39.06M35.69M | +9.4% |
| Shares Outstanding (Diluted) | 39.84M36.33M | +9.7% |
05—Questions
Frequently Asked Questions
How did Medpace's profitability change in 2017?
Income from operations increased to $64.9 million from $52.5 million, and net income rose to $39.1 million from $13.4 million. Interest expense, net fell to $7.6 million from $19.4 million, partly reflecting lower average borrowings and a lower effective interest rate under the December 2016 credit agreement. The 2016 results included a $10.7 million loss on extinguishment of debt, which did not recur in 2017.
What does the backlog tell investors about future revenue?
Backlog at December 31, 2017 was $524.4 million, up $40.5 million from $483.9 million a year earlier. The company expects approximately $285 million to $295 million of it to convert to net service revenue in 2018, with the remainder in later years. The filing cautions that backlog is not necessarily a reliable predictor of future results because contracts are generally terminable without cause, typically on 30 days' notice.
How concentrated is Medpace's customer base and ownership?
No single customer was 10% or more of net service revenue in 2017. The largest customer accounted for 5.3% and the top 10 for 32.2% of net service revenue. On ownership, Cinven owned about 46.2% of common stock and Dr. Troendle controlled about 29.2% as of December 31, 2017, and the company relies on exemptions available to controlled companies under NASDAQ rules.
What are the company's main debt and liquidity arrangements?
At December 31, 2017, the company had $152.6 million outstanding under a $165.0 million senior secured term loan and $70.0 million drawn under a $150.0 million revolving credit facility, leaving $80.0 million available. Both facilities mature in December 2021 and carry variable rates. Cash and cash equivalents were $26.5 million, and management believes sources of liquidity will be sufficient for the next 12 months and on a longer-term basis.
06—Continue